A group of genetic researchers from The Netherlands, the US, and Norway suggest a possible way to predict not only which patients are likely to have osteoporosis fractures but also when they might occur.
“Using a genome-wide association study, we were able to develop a genetic risk score to help identify individuals who are likely to fracture early. Some of these individuals can have normal bone mass density, so would not be deemed as osteoporotic by the usual scans. It is important to be able to identify such patients so that we can offer them the right treatment at an early stage,”
— Dr Carolina Medina-Gomez, from the Laboratory of Human Genetics, Erasmus MC, Rotterdam, The Netherlands
The researchers studied the fracture history of 11,351 participants in the Rotterdam Study with up to 20 years of follow-up. The aim of the Rotterdam study, which started in 1990, is to investigate factors that determine the occurrence of disease in elderly people.
The genetic risk score was derived from the largest genome-wide association study (GWAS) on BMD to date, carried out in data from the UK BioBank. A GWAS analyses a genome-wide set of genetic variants in different individuals to see if any of the variants is associated with a trait or disease, a media release from the European Society of Human Genetics explains.
Physical activity during the course of a life has an impact on the onset of osteoporosis and campaigns promoting exercise at all ages are important for preventing its early onset. But people with a genetic predisposition to early fracture could benefit from targeted interventions, not only to increase bone mass density in adulthood but also to prevent falls, for example by improving balance and muscle power. So being able to identify these patients at an early stage could lead to a better outcome for these individuals.
Widening the research to include non-European populations will be an important step forward, the researchers continue. Until now, genetic risk scores have been generated from GWAS containing mainly European populations, and do not always yield the same results in people from different backgrounds. Even though the prevalence of osteoporosis is much higher in Europeans, the study of how well the genetic risk score can predict time to fracture in other populations is crucial, they note.
“The current method of classifying patients based on bone density scans is effective, but we are trying to help those individuals with apparently normal bone mass density who suffer fractures, and it is these people the bone research community is trying to identify so that we can offer them the right intervention and treatment,” Medina-Gomez continues.
“We will still need to be able to fine-tune which PRS weighting system will allow us a more precise identification of these people, and to assess the added value of using a PRS as compared to a Fracture Risk Assessment Tool assessment as used at present by clinicians. If the PRS can help clinicians identify the group of individuals who would benefit from medication, for example, it would be an extraordinary achievement.”
Medina-Gomez presented the research recently at the 53rd annual conference of the European Society of Human Genetics, held online.
[Source(s): European Society of Human Genetics, EurekAlert]